Lataa...
The Three P’s: Parotid, PD-L1, and Pembrolizumab
We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Hindawi Limited
2019-01-01
|
| Sarja: | Case Reports in Oncological Medicine |
| Linkit: | http://dx.doi.org/10.1155/2019/2305315 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|